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Abstract
Family studies are consistent with genetic effects making substantial contributions to risk of
psychiatric disorders such as schizophrenia, yet robust identification of specific genetic variants
that explain variation in population risk had been disappointing until the advent of technologies
that assay the entire genome in large samples. We highlight recent progress that has led to a better
understanding of the number of risk variants in the population and the interaction of allele
frequency and effect size. The emerging genetic architecture implies a large number of
contributing loci (that is, a high genome-wide mutational target) and suggests that genetic risk to
psychiatric disorders involves the combined effects of many common variants of small effect, as
well as rare and de novo variants of large effect. The capture of a substantial proportion of genetic
risk facilitates new study designs to investigate the combined effects of genes and the
environment.
A genetic contribution to the risk of many psychiatric disorders has been well established by
family studies1–5, but the nature of their genetic architectures has not. Genetic architecture
refers to the number of genomic loci contributing to risk, the distribution of their allelic
frequencies and effect sizes, and the interactions of alleles in and between genes, all of
which contribute to the relationship between genotype and phenotype. Understanding
genetic architecture is the foundation on which progress in dissecting etiology is built
because it dictates which study designs for identifying risk variants are likely to be most
successful. Here we review how recent studies that employed whole-genome genotyping or
exome sequencing have contributed to a better understanding of the joint spectrum of allele
frequencies and penetrance of risk variants for psychiatric disorders. We focus particular
attention on schizophrenia (SCZ), the genetic dissection of which is further advanced than
other disorders considered in this review, including Alzheimer’s disease (AD), anorexia
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nervosa (AN), attention deficit hyperactivity disorder (ADHD), autism spectrum disorder
(ASD), bipolar disorder (BPD), major depressive disorder (MDD), obsessive compulsive
disorder (OCD) and Tourette’s syndrome (TS).
Psychiatric disorders are best classified as ‘complex traits’. The variability of such traits is a
result of a large number of factors and can be dissected into sources of variation resulting
from genetic factors, non-genetic factors and their interplay. With the exception of rare
strictly monogenic disorders, almost any trait—for example, most common diseases, brain
regional volume and the amount of DNA methylation of a particular gene in a particular
tissue—can be considered a complex trait, so long as it can be measured and varies between
individuals. In Box 1, we provide a primer on the genetic analysis of complex traits.
Box 1
Primer on genetic analysis of complex traits
Before the availability of direct measures of genetic variation at the level of DNA,
epidemiological studies on psychiatric disorders endeavored to detect robust associations
between measurable environmental factors and risk of disease, whereas genetic
epidemiologists attempted to quantify the risk in the population into genetic and non-
genetic sources of variation. Notably, one can quantify the proportion of variation in the
population resulting from genetic factors (the heritability) without knowing anything
about how many or which genetic variants underlie the trait using the observed risk to
relatives and contrasting that with what would be expected given the proportion of the
genome those relatives share by descent. Epidemiological studies have identified a
number of environmental risk factors, such as maternal infection during pregnancy and
risk of schizophrenia to their children93. Reported recurrence risks to relatives are
consistent with heritabilities of 40–80% for autism, schizophrenia and major depression.
Genetic differences between individuals in their risk to psychiatric disorders are a result
of one or more mostly unknown variants in the genomes of people. Such variants either
segregate in the population or are de novo mutations not expressed in the parents.
Segregating variants cause the observed similarity in risk between relatives, whereas new
mutations do not, apart from rare exceptions such as mutations in monozygotic twins that
arose before the embryo was split, and mutations shared by siblings as a result of
germlinemosaicism.
The contribution of a specific genetic variant to trait variation in the population is
determined by the combination of its allele frequency and its effect size. Variants are
typically classified as common, low frequency or rare if their population frequencies are
>0.01, between 0.01 and 0.001, and <0.001, respectively. At one extreme, rare variants of
large effect are by definition carried by few individuals. They may have a very large
effect on those people—for example if the variant is sufficient to cause disease—but tend
to not contribute much of the variation in the population as a result of their rarity. At the
other extreme, common variants of small effect are carried by lots of people, either in the
heterozygous or homozygous state. The increased risk of disease to an individual from
such variants may be trivial but the effect on population variance can be the same as for
the rare variant of large effect (Fig. 3 in Box 1). For example, recurrent 22q11.21
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deletions increase risk to schizophrenia from 1% to about 20–40%, yet are rare in the
population (fewer than 1 in a 1,000 individuals carry the deletion), whereas a common
variant in ZNF804A increases risk from 1 to 1.1% per allele, but is common (a
proportion of 0.8 in the population has one or two alleles): both contribute about the same
amount of variation in liability to schizophrenia (that is, r2 ~0.1%)77. The majority of
risk alleles for schizophrenia, common and rare, are likely to explain substantially less of
the variation than these examples (Fig. 3 in Box 1).
A positive family history is often assumed to be indicative of inherited risk variants,
whereas ‘sporadic’ cases of disease (that is, those with a negative family history) are
sometimes assumed to harbor new (de novo) high penetrance mutations. Although there
is some evidence for this classification in SCZ (for example, see refs. 44,60), and
although focusing on sporadic cases makes sense when searching for de novo mutations,
it is worth noting that a negative family history is expected for highly polygenic, low
prevalence disorders (for example, SCZ)94. Thus, under polygenicity, the delineation of
affected individuals as familial and sporadic may be misleading. More data is needed to
determine which genetic models are most appropriate for psychiatric disorders, but even
for non-psychiatric diseases, such as amyotrophic lateral sclerosis, where there are clear-
cut examples of Mendelian fully penetrant mutations, there is emerging consensus that
the distinction between familial and sporadic amyotrophic lateral sclerosis is artificial95.
Geneticists have used a number of ‘whole genome’ toolboxes to try to discover genes and
genetic variants that are associated with risk to psychiatric disorders: genetic
epidemiology studies to quantify the combined effect of the entire genome to risk of
disease, genome-wide linkage studies, GWASs and WES studies12. In the near future we
can add whole-genome sequencing, which essentially will supersede genome-wide
linkage studies, GWASs and WES studies.
Segregating variants in the population that predispose to psychiatric disorders are the results
of our evolutionary past. The evolutionary forces that shaped our modern genomes include
mutation, natural selection and genetic drift. Natural selection acts on ‘net’ fitness, which is
much more than fitness with respect to any individual disease. Although there are multiple
theories of what our genomes should look like with respect to variants that predispose to
psychiatric disorders and other complex traits6–8, testing their predictions awaits a better
understanding of the genetic architecture of complex traits. Broadly speaking, for any given
complex trait, the distribution of genetic variance explained as a function of minor allele
frequency is expected to be uniform under a neutral evolutionary model, but should be
shifted toward lower minor allele frequencies to the extent that alleles affecting the trait
have been under selection9. Yet, irrespective of evolutionary arguments, we can study
human genomes here and now to understand why some individuals are at higher risk of
disease than others. The genomics revolution, particularly the ability to interrogate the entire
genome through developments in high-throughput technologies such as genome-wide
genotyping and sequencing, has provided the tools to dissect the genetic variation that was
inferred from genetic epidemiological studies into contributions from individual variants.
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Mutation, polymorphism, gene and pathway discovery
Important advances in psychiatric genetics have been made in recent years, with many
replicated discoveries of common, rare and de novo risk factors that are converging on
specific pathways and biological mechanisms. These successes have predominantly come
about as a result of the experimental design of genome-wide association studies
(GWASs)10,11 and, in particular, the international community combining resources and
results across multiple GWASs and copy number variation (CNV) studies to maximize
sample size and statistical power. Whole-exome sequencing (WES) has also begun to shed
light on the role of rare and de novo coding sequence variation, particularly in autism. The
flow of discoveries from these unbiased genome-wide methods stands in contrast to the
weak and largely inconsistent findings from candidate gene studies12.
GWAS
At the time of writing this review, GWASs have identified >100 independent loci for SCZ13,
20 loci for AD14, eight loci for BIP15, one locus for ASD16, and none for other common
psychiatric disorders, including ADHD17, AN18, MDD19, OCD20 and TS20 (Fig. 1). In
addition, cross-disorder GWAS meta-analyses had identified three loci for a combined SCZ-
BPD phenotype21 and four loci for a broader psychiatric phenotype spanning ASD, ADHD,
BPD, MDD and SCZ22. These genetic findings surpass accepted standards for genome-wide
significance (P < 5 × 10–8) and replication in human genetics; the stringent type 1 error
threshold of 5 × 10–8 corresponds to a Bonferroni correction of 0.05 divided by 1,000,000
tests, which is the estimated number of independent common variants across the human
genome23. The overt success for SCZ, the ‘flagship’ disorder of the Psychiatric Genomics
Consortium (PGC)24, is largely explained by greater sample size (that is, >35,000 cases
compared with a maximum of ~17,000 cases for any other disorder), which was achieved by
the PGC combining data across >50 studies13. Indeed, no single locus had been robustly
associated with SCZ when sample sizes were similar to those currently available for many
other disorders (for example, ADHD: ~900 cases17). MDD is an exception, given that no
discoveries were made in the most recent PGC mega-analysis19 (9,240 cases, 9,519
controls), a study similar in scale to the PGC’s initial SCZ GWAS (9,394 cases, 12,462
controls), which identified seven loci21. However, sample sizes approximately five-fold
greater than SCZ are predicted to be necessary for GWAS discovery in MDD, mostly as a
result of its high population prevalence25 (Fig. 2). Phenotypic heterogeneity may also be a
factor contributing to differential success of GWAS in psychiatric disorders (discussed
below). These considerations aside, the results for SCZ, the largest GWAS to date for any
psychiatric disorder, show what might reasonably be expected for other disorders from
larger studies that are currently in the pipeline.
The trajectory of GWAS discovery for SCZ, which increased from 1 locus26,27 to 7 (ref. 21)
to 22 (ref. 28) to 62 (ref. 29) to >100 (ref. 13) as the number of cases increased from ~3,000
to >35,000, is not dissimilar to that of other (non-psychiatric) diseases (Fig. 1). Admittedly,
late-onset diseases, including AD30 and age-related macular degeneration31, and some
autoimmune diseases (for example, Crohn’s disease)32 achieved success earlier, often with
first generation technologies such as linkage mapping and GWASs of small samples, but
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these discoveries involved risk alleles that explain an unusually large proportion of the total
genetic risk (for example, APOE in AD). GWAS loci identified for SCZ, as with the
majority of GWAS discoveries across the breadth of medicine, are very common (that is, the
risk allele is often the major allele), have small effect size (for example, 1.1% absolute risk
when the population prevalence is 1%) and individually explain only a small fraction of the
total genetic risk (Fig. 3 in Box 1). The underlying genetic architecture is highly
polygenic21,26,28, as we discuss below, a fact that has driven, and continues to drive,
international efforts coordinated by the PGC to assemble ever-larger samples for meta-
analyses33.
Why should neuroscientists’ care about GWAS findings in psychiatric disorders given that
identified loci have such small effects? First, although verified GWAS effects are usually
small individually, their cumulative effect is not. Genetic profile scores derived from very
large discovery samples can be applied to small target samples, such as those used in
neuroscience studies, to facilitate more powerful experiments, for instance, by enabling
stratification of samples according to upper and lower deciles of genetic risk. Second, there
are now many examples of diseases for which GWAS has highlighted relevant biology (for
example, see refs. 31,34), including known drug targets35,36. For instance, numerous genes
identified in a GWAS meta-analysis for rheumatoid arthritis are the targets of known drugs
that are effective therapies for this disease37, and the same is true for genes underlying
natural variation in LDL levels that are the targets of statins38. Results from the latest
GWAS for SCZ suggest that similar insights may be forthcoming in psychiatric disorders,
given that identified loci include known targets of existing antipsychotics13. These examples
indicate that, although GWAS loci have small effect size, they nonetheless may help identify
targets for novel therapeutics38 or may identify existing drugs that can be repurposed for
treatment of diseases that they were not initially developed to treat36. More broadly, and
consistent with other complex diseases (for example, inflammatory bowel disease39) and
traits (for example, height40) for which large numbers of genetic associations have been
identified, the 100+ GWAS loci identified for SCZ converge on biological pathways
relevant to disease etiology, including neuronal calcium ion channel signaling, altered
immune function and MIR137-mediated post-transcriptional regulation of gene
expression13. Functional investigation of the biological basis of genetic associations in these
pathways represents a formidable challenge and will be far more difficult than that for rare
variants with larger effects. We are in the very early days of addressing this challenge, but
there is nonetheless potential for such efforts to make profound contributions to our
understanding of disease pathogenesis.
Structural variation studies
At the opposite end of the risk allele frequency spectrum, rare and de novo submicroscopic
chromosomal deletions and duplications termed CNVs have been implicated in a range of
psychiatric disorders. The unbiased genome-wide analysis of large CNVs (>100 kb) has
been facilitated by data from high-density genomic arrays used in GWAS. Over the past
decade, such studies have established that large rare (<1% frequency in the population)
CNVs, particularly those arising de novo in the parental germline, occur at higher
frequencies in ASD41,42, SCZ43,44 and ADHD45 than in healthy controls, implying that
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some events contribute to risk. Rare CNVs have also been implicated in BPD, particularly
early onset disease46, but the evidence is inconsistent47 and the contribution may be less
than for ASD and SCZ. In addition to evidence for increased CNV burden, about a dozen
recurrent CNVs have been identified, including deletions on chromosomes 2p16.3 (in the
NRXN1 gene), 3q29 and 17q12, duplications on 7q11.23, 7q36.3 (in the VIPR2 gene),
15q11.2 and 16p13.11, and both deletions and duplications at 1q21.1, 15q13.3, 16p11.2 and
22q11.21 (refs. 45,48–51). At several loci there is evidence that ASD and SCZ are
associated with reciprocal events; that is, deletions predispose to one disorder and
duplications the other52. Most of the identified loci span multiple genes and confer risk for a
range of psychiatric and neurodevelopmental disorders48,49, consistent with other evidence
for shared genetic etiology across diagnostic boundaries. Odds ratios are high compared
with common loci, ranging from ~2 to >20 (refs. 48,49), but their frequency is very low in
the general population (that is, the majority have a frequency < 0.001) and so large samples
are nonetheless required for discovery and replication (similar to that for GWAS). For some
loci, penetrance for ASD appears to be higher in males than females (for example,
16p11.2)53, and de novo events in affected girls are more functionally disruptive than those
in affected boys41,53. This suggests that girls have greater resistance to ASD from genetic
factors, consistent with the ~4:1 male bias in incidence, although the mechanisms
responsible for this pattern remain to be deciphered41,53.
WES
WES involves the targeted enrichment and high-throughput sequencing of all coding exons
and non-coding RNAs in the genome. In recent years, the first WES studies investigating
rare sequence variation in common psychiatric disorders have been published, with most
attention to date on de novo mutations in ASD (for example, see refs. 54–57) and SCZ (for
example, see refs. 58–60). WES studies of other psychiatric disorders are currently
underway. Sequence-based discovery of genes involved in neurodevelopmental disorders is
reviewed by Hoischen and Eichler61, so we focus here on implications of these studies for
genetic architecture, with a brief overview of key findings.
Sample sizes for WES are still modest (for example, hundreds of families, up to ~5,000
cases and controls) compared with GWAS and CNV analyses, but results suggest an
important, albeit limited (see below), role for de novo coding point mutations, particularly in
early-onset neurodevelopmental disorders (for example, see refs. 54–57,62). Several key
findings have emerged. First, about three quarters of de novo point mutations have a
paternal origin and the mutation rate is correlated with paternal age at conception (for
example, see refs. 63,64; Fig. 4). Advanced paternal age is a risk factor for a range of
psychiatric disorders, including ASD and SCZ65, but it remains unclear whether this risk is
explained by the increased mutation rate or whether other mechanisms (for example,
delayed fatherhood as a result of high polygenic risk66; age-related epigenetic changes67)
have a role. Second, ASD probands harbor an excess of gene-disrupting mutations (for
example, stop gain/loss, splice altering, frameshift; Table 1), particularly in brain-expressed
genes54,57. Notably, this enrichment is restricted to probands with low IQ68. Given that
similar enrichment has been reported in intellectual disability (for example, see ref. 62),
these findings raise the question of whether gene-disrupting de novo mutations are related to
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ASD per se or to intellectual impairment given ASD, or, conversely, to severe forms of ASD
characterized by low IQ. Notably, in SCZ, the burden of gene-disrupting mutations is higher
in SCZ probands with premorbid cognitive impairment compared with those without such
impairment58, which is an interesting parallel to the enrichment of such mutations in ASD
probands with low IQ. The available evidence does not support an overall excess of gene-
disrupting de novo mutations in SCZ58, although one exception is a study (N = 146 case
trios) involving SCZ probands that were carefully screened for a negative family history of
psychosis60, and it is possible that disruptive mutations are enriched in such cases. These
points aside, there is some evidence for an excess of disruptive mutations in SCZ in several
postsynaptic gene sets (although see refs. 41,60 for exceptions). These include members of
the activity-regulated cytoskeleton-associated protein (ARC) and NMDA receptor
(NMDAR) gene complexes and in genes associated with the fragile-X mental retardation
protein (FMRP)58. These gene sets were also enriched in a parallel SCZ case-control WES
study59 and in ASD (NMDAR, FMRP)54 and intellectual disability (ARC, NMDAR,
FMRP), pointing to substantial overlap of de novo signal between disorders58,59. An excess
of disruptive mutations in SCZ has also been identified in genes involved in voltage-gated
calcium ion channel signaling59, a notable overlap with GWAS findings13.
A third noteworthy finding is that specific genes have been identified in ASD and SCZ with
recurrent gene-disrupting de novo mutations that exceed the number expected by chance. In
SCZ, a single recurrence has been reported in the TAF13 gene58, whereas, for ASD, a total
of seven genes with recurrences have been identified in 1,043 families16,21,26. These are
important findings given that specific mutations in single genes are expected to be more
amenable to functional follow-up than GWAS loci or multigenic CNVs. Attempts to identify
specific genes using gene-based testing of segregating rare (as opposed to de novo) variants
in WES case-control studies of SCZ59 and ASD69 have so far been unsuccessful (although
see ref. 70), and much larger sample sizes, equivalent to those in current GWASs, are likely
to be necessary59. This also applies to whole-genome sequencing studies, which examine
variants that exist between as well as within genes, which are expected to become
increasingly prevalent in coming years.
Synthesis: genetic architecture and mutational target size
The results from recent GWAS, CNV and WES studies are enabling, for the first time,
empirical assessment of fundamental questions about the genetic architecture of psychiatric
disorders. For each disorder, how many loci are there? What are their frequencies and effect
sizes? Taken together, how much of the heritability can be accounted for? How do the
different disorders compare and how do they compare to non-psychiatric diseases? To what
extent does the genetic contribution to one disorder overlap with others? And what is the
evidence for gene-gene interaction? These are important questions because, without this
knowledge, the field is operating in the dark when it comes to dissecting genetic etiology.
Newly developed statistical methods that assess the joint contribution of common genetic
variation across the genome are beginning to provide initial answers to these questions. The
available evidence suggests that psychiatric disorders, including SCZ71, BPD71, ASD71,
ADHD71, MDD71, OCD20, TS20 and AD72, are highly polygenic, with between one third
and a half of the heritability being explained by common genetic variation distributed across
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the genome. In the case of SCZ, an estimated 8,300 independent common loci collectively
account for up to 50% of the genetic risk28. A high degree of polygenicity (that is, high
number of contributing genes or mutational target size) appears to be typical for most
complex traits (for example, height73) and common diseases (for example, Crohn’s
disease74, type I diabetes74) examined to date75. However, although a substantial proportion
of the genetic risk for some autoimmune diseases is a result of alleles that individually
explain a substantial proportion of the heritability (for example, 1%), currently available
data suggest that the polygenic risk for schizophrenia is dominated by alleles with very
small effects (that is, 0.05% or less; Fig. 3 in Box 1). This is probably true for most
psychiatric disorders (with AD being an exception). Whole-genome analysis methods also
support substantial overlap of common genetic variation between disorders, in most
instances consistent with clinical overlap and evidence for comorbidity from
epidemiological studies.
A role for rare variants in psychiatric disorders has been well established by CNV and WES
studies, but the overall contribution of rare variation is less well understood compared with
common variation because coverage and sample sizes are not yet optimal. This is also true
for low-frequency variation. A substantial contribution is possible if the heritability not
explained by common variation (for example, half to two thirds for most disorders) is
predominantly a result of rare and low-frequency variants, a question that will only be fully
resolved by whole-genome sequencing studies that completely ascertain all genetic variation
in large samples of cases and controls. In the interim, the PGC has developed the
PsychChip, a single nucleotide polymorphism (SNP) array that features ~250,000 functional
protein-coding variants, most of which are low frequency, in addition to high-density
coverage of known and suggestive psychiatric disorder loci and a genome-wide backbone of
common variation (enabling integration with existing data sets). In excess of 100,000 cases
across multiple psychiatric disorders will be genotyped by the PGC with this array in the
coming year, which should provide initial insights into the role of low-frequency variation in
psychiatric disorders.
The overall contribution of de novo CNVs and coding mutations is also an open question,
but the majority of new mutations do not contribute to heritability estimates76, which are
high for most psychiatric disorders (that is, ~0.6–0.8). Currently available WES data for
ASD are consistent with ~5–10% of affected individuals harboring a damaging de novo
point mutation with an odds ratio of ~5–20 (ref. 55). Importantly, in the context of using
WES to assist clinical diagnosis, a genetic model for ASD involving fully penetrant
mutations in many genes can be rejected55 (although a proportion of cases may harbor new
highly penetrant mutations). Existing CNV and WES studies are consistent with GWAS
evidence for a large mutational target in psychiatric disorders. The data on de novo coding
mutations in ASD suggests that between 370 (ref. 54) and 1,000 (ref. 57) genes contribute to
disease, and similar figures have been reported in schizophrenia (for example, N = 850
genes)60.
Although it is clear that genetic variation for psychiatric illness spans the entire spectrum of
allele frequencies, there is evidence that the relative importance of rare and common
variation may differ between disorders. For instance, SNPs with a minor allele frequency
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<0.05 explain 21% of the heritability for TS, compared with 0% for OCD (in analyses that
compared the two case samples to a common control), despite substantial overlap of
common variation between these disorders20. Studies that ascertain rare and low-frequency
variation in large samples will help to clarify the distribution of genetic variation as a
function of allele frequency in these and other disorders.
The heritability explained by individual common and rare variants identified to date is
approximately the same77 as a result of an inverse relationship between allele frequency and
effect size (Fig. 3 in Box 1). This relationship is predicted by evolutionary theory due to the
action of selection driving alleles with large effect size to lower frequency6, although it is
important to note that many rare and low-frequency variants with small effect size are also
likely to exist. The precise nature of the joint distribution of risk allele frequencies and effect
sizes is yet to be elucidated.
Relationship between disorders: new insights from genomic data
In most other branches of medicine, diagnosis has moved on from classification based on
self-reported symptoms and clinical observation to incorporate more objective tests of
disease78. Although the classification system in psychiatry has been standardized and
regularly revised since the 1980s, the biological validity of the current diagnosis system is
unknown. Probing underlying biology is problematic when ‘case-ness’ is often the only
consistently recorded phenotypic data available for large-scale analyses78. Both comorbidity
between disorders and heterogeneity within disorders may be a reflection of the diagnostic
label in the context of the current nosology. Dimensional scales have been proposed (for
example, see ref. 79), but have not been widely adopted. A genetic contribution to the
relationship between psychiatric disorders has been established from both clinical (for
example, see ref. 80) and epidemiological (for example, see refs. 1,2) studies, showing
increased risk of disorders in the relatives of those affected. However, accumulating large
enough samples to achieve accurate results is a limiting factor.
The genomics era has provided powerful approaches to explore the genetic relationship
between disorders in new ways. Specific variants associated with multiple disorders and
cross-disorder phenotypes have been identified21,22, as discussed above. These studies are
too underpowered to identify the majority of shared genetic factors, but currently available
GWAS samples collected independently for different disorders can be used to interrogate
the genetic relationship between disorders at a genome-wide level. In this paradigm,
although all individuals are unrelated in the classical sense, they nonetheless share genomic
segments through common ancestors. Thus, genome-wide genotypes can be used to
determine whether cases are genetically more similar to each other (that is, across disorders)
than to controls74 and to calculate the correlation between disorders on the basis of genome-
wide SNPs (the SNP correlation)81. Given that the data sets have been collected
independently, any relationship detected between disorders is directly attributable to shared
DNA variants and contamination by shared environmental factors seems unlikely. The
estimate of the genome-wide SNP correlation applied to SCZ and BPD data was 0.68 (s.e. of
0.04), implying important shared genetic etiology (Fig. 5)71. Theoretical modeling of
potential misdiagnosis between disorders82,83 cannot explain the high correlation84. In
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contrast, a high genetic correlation between disorders is likely to generate individuals with
mixed symptoms that may lead to changing diagnoses under the current nosology71. It is
noteworthy that SNP correlations calculated between independently collected SCZ data sets
were ~0.9 (Fig. 5), implying that the diagnostic classification system does indeed split out a
genetically more homogeneous subset from the psychiatric spectrum71. Notably, the SNP
correlations calculated between BPD sets were more variable (0.55–0.88), perhaps
suggesting more genetic heterogeneity within BPD (Fig. 5). The same method has been
applied to all pairs of disorders in the psychiatric genomics consortium (that is, SCZ, BPD,
MDD, ADHD and ASD)71. These analyses demonstrated a moderate genetic relationship
tagged by common polymorphisms between MDD and both BPD (0.47, s.e. 0.06) and SCZ
(0.43, s.e. 0.06), implying an underlying genetic vulnerability to psychiatric disorders
traditionally considered as adult onset disorders (Fig. 5).
Revisiting old questions with new data
The availability of genome-wide genetic data facilitates much more than gene and pathway
discovery. It allows new experimental designs to address old scientific questions with new
data. One example is the study of pleiotropy, whereby genes or genetic variants influence
more than one trait. Pleiotropy is widespread, not just in humans, but across species85.
However, pleiotropy has been difficult to study in humans with family designs because
multiple diseases and disorders are unlikely to co-segregate in families with sufficient
prevalence, even if there are shared genetic factors. The cross-disorder study, described
above, is one specific example of a population-based study that links individuals by
genome-wide similarity. Notably, in these designs, different individuals can be measured for
different traits. These methods are being used to explore epidemiological puzzles such as
different rates of immune disorders and cancers in people with and without schizophrenia
(for example, see ref. 86).
The importance of genotype × environment interactions is another longstanding question
that can be addressed with new genome-wide data. Such interactions have been suggested
for psychiatric disorders, but we are not aware of any statistically significant and replicable
interactions. The likely reason is that samples to date have been small and most studies have
focused on only a small subset of candidate gene polymorphisms87. Large genetically and
environmentally informative samples will be needed to achieve the statistical power required
given small expected effects. The findings from whole-genome studies can overcome some
of these limitations by using the aggregate of multiple genetic risk factors identified in large
genotyped samples to obtain a better estimate of genotype and applying this in smaller
genotyped samples that are informative for relevant environmental risk factors. This design
could be used to test whether genotype and environment act multiplicatively on risk or
whether there is a real interaction88.
Another hypothesis that was posed many years ago is the relationship between paternal age
and risk of disease in offspring, but data on de novo mutation rates and the identification of
specific new mutations has not been feasible until recently. The availability of direct
estimates of the de novo mutation rate from sequencing studies in families offers new
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opportunities for evaluating the relationship between paternal age, new mutations and the
increased risk of ASD, SCZ and other disorders.
Conclusions
The genomics era has demonstrated the value of large data sets and international consortia
and has narrowed down the genetic architecture dramatically. In Box 2, we summarize the
current state of knowledge of genetics in psychiatric disorders. Efforts to accumulate and
process very large samples for genotyping and sequencing are underway for multiple
disorders and we can be confident that many additional genetic associations, common and
rare, will be identified. The rate-limiting step for the field is now the availability (or lack
thereof) of standardized phenotype data in large cohorts. The development of innovative
‘next-generation phenotyping’ methods for the quick and cost-effective collection of
phenotype data in large samples should be a priority. Such efforts will require international
collaboration, and should be geared toward testable hypotheses in evolution and
epidemiology. Possibilities include the investigation of genotype × environment interactions
(provided the right environment risk factors can be identified), and the use of Mendelian
randomization to infer causal effects of modifiable environmental risk factors. A third
possibility relates to natural selection, for instance, comparing fecundity in those with large
de novo CNVs versus those without. This type of approach is likely to be complemented by
endophenotype studies, including brain imaging89, and by efforts to characterize the
functional basis of genetic associations. Together, these approaches, by refining our
understanding of etiology, hold the promise of better treatments and prevention for a group
of disorders that account for about one third of the global burden of disease90.
Box 2
What we know and don’t know about the genetics of psychiatric disorders
• Heritability estimates for most psychiatric disorders are high, ranging from 0.4–
0.8 (refs. 1–4). These estimates are consistent across studies and cannot be
explained by perceived ‘flaws’ in twin analyses.
• Psychiatric disorders are highly polygenic (for example, ref. 71), meaning that a
large number of genomic loci contribute to risk (that is, the genome-wide
mutational target is high). No single variant explains more than a small fraction
(for example, ~0.1%) of the genetic variance (with the exception of AD, for
which much of the variance is explained by a few common loci with large
effects), which implies that large sample sizes are required for genetic
discoveries77.
• Genetic variation for psychiatric disorders spans the entire allelic spectrum from
common to rare, and includes structural variation (CNVs) as well as SNPs.
GWASs have identified >100 common loci for SCZ13 and smaller numbers for
other disorders14–16. These findings have survived rigorous attempts at
falsification and cannot be explained by population stratification. About a dozen
rare CNVs have been identified, many in association with multiple disorders48.
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• De novo mutations, including CNVs41–44,46,49 and single base
mutations54–58,60, are also important risk factors, and emerging evidence
suggests that presence of these variants in the context of psychiatric disorders is
associated with impaired cognition, consistent with evidence of de novo
mutations in intellectual disability. The high heritability of most disorders limits
the potential contribution of new mutations, the majority of which do not
contribute to heritability estimates.
• Common risk loci (MAF > 0.05) are associated with small effect size (odds ratio
~1.05–1.2), whereas identified rare variants, including de novo mutations, have
larger effects (odds ratio ~2 to >20). Common variants with odds ratios >1.5 can
be ruled out for most disorders (excepting AD). Conversely, rare variants with
smaller effects (odds ratio < 2) are likely to exist, but current studies lack the
power to detect them. Low-frequency variants are poorly surveyed, but initial
studies in SCZ suggest few if any “Goldilocks” variants (low-frequency variants
with odds ratios ~1.5–2; that is, not too big, not too small) exist59.
• Genetic variation tagged by common SNPs accounts for between one-third and
half of the heritability for most disorders (for example, see refs. 19,26,28,71).
These estimates are not inflated by population stratification and largely resolve
the controversy of missing heritability (that is, that GWAS findings explain only
a small proportion of the heritability estimated by family studies), as they imply
that much of the heritability is merely hidden (that is, many common loci exist
that do not surpass the threshold for genome-wide significance in GWAS).
• The contribution of rare variation is less well understood because coverage and
sample size are not yet optimal, but it may be substantial if variation not
explained by common variation (that is, half to one third) is a result of rare
variants. Larger studies and improved ascertainment of rare variation (for
example, by whole-exome and whole-genome sequencing) will be needed to
clarify the overall distribution of genetic variance as a function of allele
frequency.
• There is strong evidence for sharing of common genetic variation (pleiotropy)
between disorders, particularly SCZ, BPD and MDD71. Rare and de novo CNVs
also exhibit substantial overlap between disorders96, and there is emerging
evidence that the same may be true for rare and de novo point mutations58,59.
The latter is in the form of shared enrichment across disorders of mutations in
particular gene sets (for example, targets of FMRP), although whether this
overlap extends to the level of specific mutations is currently unclear.
• No fully penetrant mutations for SCZ have been identified, and the idea that
SCZ is a set of monogenic disorders can be ruled out. Single mutations
sufficient to cause illness are known for ASD, but, similar to SCZ, the idea that
all cases can be explained by single mutations is inconsistent with the empirical
data.
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• Although it’s clear that many common and rare variants exist for psychiatric
disorders, we do not understand how these variants combine to influence disease
pathogenesis and phenotypic heterogeneity. One possibility is that all risk
variants, common and rare, contribute to an underlying liability for disease with
individuals exceeding a threshold being affected. This could involve background
common variation increasing or decreasing the effects of one or multiple rare
high penetrance mutations, although other possible mechanisms exist and
differentiating between them represents a major future challenge for the field.
• There are few (if any) causal variants known and the precise joint distribution of
effect size and risk allele frequency, although coming into focus, is currently
unknown. The interpretation of empirically derived joint distributions will
depend on the biological validity of the diagnostic constructs.
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Figure 1.
The trajectory of GWAS discoveries for schizophrenia and other psychiatric disorders in
comparison to Crohn’s disease and inflammatory bowel disease. The number of independent
genome-wide significant (P < 5 × 10–8) loci are plotted as a function of the numbers of
cases in the largest meta/mega-analysis. The inset shows detail for studies with fewer than
6,000 cases. CD-IBD, Crohn’s disease and inflammatory bowel disease (including CD and
ulcerative colitis); Cross-disorder: broad psychiatric phenotype spanning ASD, ADHD,
BPD, MDD, SCZ; SCZ-BPD, SCZ and BPD.
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Figure 2.
Not all GWASs are created equal under a polygenic architecture. For the same sample size,
less common diseases have more power. Statistical power for detection of gene variants
associated with disease for different disorders given the same sample size (type-1 error of
10–8, sample size of 10,000 cases and 10,000 controls). Different combinations of allele
frequency and effect size can generate the same variance in liability. Examples of disorders
with the prevalence shown are motor neuron disease (MND), SCZ and MDD.
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Figure 3.
Genetic discoveries for SCZ, irrespective of risk allele frequency, variant type (SNP or
CNV) or discovery method (GWAS or CNV analysis), explain approximately the same
proportion of the genetic variance. The red line defines a constant r2 of 0.04%, assuming a
1% prevalence of schizophrenia. Note that the population prevalence of some CNVs is set to
10–4 for convenience; some have not been observed in healthy controls and so the true allele
frequency (and variance explained) will be lower.
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Figure 4.
Paternal age at child’s conception is associated with the burden of de novo mutations in the
child’s genome (Poisson regression, P < 2 × 10–16, linear slope = 1.75 mutations per year).
Data are from refs. 63 (N = 78) and 64 (N = 10).
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Figure 5.
Quantifying the genetic relationship between independent data sets through the SNP
correlation20,71,91,92. AA, African American; CHN, Chinese; EUR, European including
European American.
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Table 1
De novo gene-disrupting mutations are enriched in ASD
Mutation class Mutations/person (mean/variance) P*
Probands Siblings
All 1.10 (1.23) 0.97 (1.00) 0.05
Silent 0.35 (0.37) 0.36 (0.41) 0.59
Missense 0.61 (0.64) 0.54 (0.53) 0.21
Gene disrupting** 0.15 (0.14) 0.06 (0.07) 2.63 × 10−5
Data are from 590 ASD families with one affected child and one or more unaffected siblings (ref. 57, n = 200; ref. 54, n = 343; ref. 56, n = 47).
*
Poisson regression with paternal age at conception fitted as covariate.
**Stop gain/loss, frameshift, essential splice site
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